Exhibit 99.1 ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates WINSTON-SALEM, N.C., November 10, 2025 – ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and provided regulatory and clinical updates. "The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week fu ...